| CCY | SZE(M) | TNR | MTY | RNK | MO | SP | FI | TYPE | BNCH | IPT | GDNC | SPRD | CPN | NIC | PRICE |
|---|
| EUR | 850.000 | 4 | Mar-26 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Swaps | MS+90 a | MS+65 a | 55 | 1.25% | - | 99.80600 |
| EUR | 750.000 | 6 | Mar-30 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Swaps | MS+120 a | MS+90 a | 75 | 1.75% | - | 99.89600 |
| EUR | 750.000 | 12 | Mar-34 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Swaps | MS+140 a | MS+110 a | 100 | 2.13% | - | 99.27900 |
Tranche Comments
4 yr: Book size: 3600; Registration: Reg S Only; Comments: EUR850m(upsized from EUR750m) 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%;
6 yr: Book size: 3900; Registration: Reg S Only; Comments: EUR750m 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%;
12 yr: Book size: 3600; Registration: Reg S Only; Comments: EUR750m 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%;
Guarantor(s)
GlaxoSmithKline PLC
Use of Proceeds
To fund pre-demerger dividends